Antibody responses after a single dose of AstraZeneca Covid-19 vaccine in previously infected individuals were similar or higher compared to SARS-CoV-2 naïve participants who received two doses of Pfizer mRNA vaccine.
Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2 – EBioMedicine Commentary (on the preprint): Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study – News Medical Related: More data showing one dose of Pfizer vaccine may be enough for individuals who’ve had COVID. […]
The post Antibody responses after a single dose of AstraZeneca Covid-19 vaccine in previously infected individuals were similar or higher compared to SARS-CoV-2 naïve participants who received two doses of Pfizer mRNA vaccine. appeared first on Links Medicus.
Perspective | Don’t panic, but breakthrough cases may be a bigger problem than you’ve been told.
Don’t Panic, But Breakthrough Cases May Be a Bigger Problem Than You’ve Been Told – Intelligencer Commentary on Twitter (thread – click for more) The vaccines are still performing quite well in preventing severe disease. But with Delta they are doing much worse in stopping transmission. Breakthroughs are probably now 10-20% of new infections, […]
The post Perspective | Don’t panic, but breakthrough cases may be a bigger problem than you’ve been told. appeared first on Links Medicus.
FDA authorizes additional Covid-19 vaccine dose for certain immunocompromised individuals – Other fully vaccinated individuals do not need an additional vaccine dose right now.
Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals – U.S. Food & Drug Administration Commentaries: Statement on FDA Authorization of Supplemental Vaccine Dose for Immunocompromised Patients – Infectious Diseases Society of America CDC, FDA recommend COVID booster for immune-compromised – CIDRAP FDA authorizes additional dose of Covid-19 vaccine for the immunocompromised […]
The post FDA authorizes additional Covid-19 vaccine dose for certain immunocompromised individuals – Other fully vaccinated individuals do not need an additional vaccine dose right now. appeared first on Links Medicus.
Opinion: Time for a smart approach to boosters.
Time for a Smart Approach to Boosters – Think Global Health
The post Opinion: Time for a smart approach to boosters. appeared first on Links Medicus.
How COVID-19 will change the management of other respiratory viral infections.
How COVID-19 will change the management of other respiratory viral infections – Intensive Care Medicine Commentary on Twitter Still in the midst of #SARSCoV2 #pandemic, still so much to learn… but #COVID19 experience should transform approach to research on RVIs?antiviral therapy?corticosteroids?specific immune modulation?anticoagulation?respiratory support#COVIDFOAM https://t.co/WVKRSJARvl pic.twitter.com/qMkB4tkz06 — Intens Care Med (@yourICM) August 11, 2021 […]
The post How COVID-19 will change the management of other respiratory viral infections. appeared first on Links Medicus.
How do vaccinated people spread Delta? What the science says.
How do vaccinated people spread Delta? What the science says – Nature
The post How do vaccinated people spread Delta? What the science says. appeared first on Links Medicus.
Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).
Could This Be Our First Effective, Inexpensive, Widely Available Outpatient Treatment for COVID-19? – HIV and ID Observations Related: Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19
The post Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine). appeared first on Links Medicus.
Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.
Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison – American Family Physician Related: Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children. Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) […]
The post Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison. appeared first on Links Medicus.
M-A of randomized trials: proton pump inhibitors for gastro-esophageal reflux disease does not improve outcomes in patients with asthma.
Randomised trials of proton pump inhibitors for gastro-oesophageal reflux disease in patients with asthma: an updated systematic review and meta-analysis – BMJ Open
The post M-A of randomized trials: proton pump inhibitors for gastro-esophageal reflux disease does not improve outcomes in patients with asthma. appeared first on Links Medicus.
[Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar – medRxiv Related: Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed. Commentary on Twitter New and important data on Delta breakthrough infections, large Qatar experience and follow-up of > 1.2 million vaccinees https://t.co/2ye1Kz9OPV […]
The post [Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7% for Pfizer and 100.0% for Moderna. appeared first on Links Medicus.